Diagnostic Performance of Two Different Techniques to Quantify CMV‐Specific Cell‐Mediated Immunity in Intermediate‐Risk Seropositive Kidney Transplant Recipients
Transplant Infectious Disease · 2026-01 · 28 (1)
DOI: 10.1111/tid.14437 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Transplant Infectious Disease, online erschienen am 10.01.2025. Verfasst von Mario Fernández-Ruiz und 15 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, …. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Kidney Transplantation, Cytomegalovirus, Immunity, Cellular. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, co-funded by the European Union, Generalitat Valenciana plan GenT.
Abstract (Originalsprache)
Background
Kidney transplant (KT) recipients at intermediate risk for cytomegalovirus (CMV) infection constitute a potential target for individualized prevention strategies informed by the CMV‐specific cell‐mediated immunity (CMV‐CMI). The optimal method for the functional assessment of CMV‐CMI in this group remains unclear.
Methods
We included 74 CMV‐seropositive KT recipients that did not receive T‐cell‐depleting induction and were managed by preemptive therapy. CMV‐CMI was monitored at baseline and months 1, 3, 6, and 12 by intracellular cytokine staining (ICS) and a interferon (IFN)‐γ‐release assay (QuantiFERON‐CMV [QTF‐CMV]). Both methods were compared for discriminative capacity (areas under the receiving operating characteristic curve [auROCs]) and diagnostic accuracy to predict protection against high‐level (≥1000 IU/mL) CMV DNAemia and/or disease.
Results
Eighteen patients (24.3%) experienced high‐level CMV DNAemia or disease. There were no significant differences in the discriminative capacity to predict protection of CMV‐specific CD8+ (auROC: 0.719) and CD4+ T‐cell counts (auROC: 0.664) enumerated by ICS and IFN‐γ production measured by QTF‐CMV (auROC: 0.666). Optimal cutoff values of ≥9.8 CMV‐specific CD4+ T‐cells/µL and ≥5.7 CD8+ T‐cells/µL by ICS yielded excellent specificity (95.7% and 86.9%, respectively) and positive predictive values (PPVs) (>98.0%), but a sensitivity below 60%. A reactive QTF‐CMV (IFN‐γ ≥0.2 IU/mL) provided good sensitivity (81.6%) and PPV (92.5%), at the expense of a poor specificity (22.2%).
Conclusions
The discriminative capacity to predict immune protection against clinically relevant CMV infection among intermediate‐risk KT recipients was comparable for ICS and QTF‐CMV. A selected ICS threshold may provide better specificity than the interpretative cut‐off values currently recommended for QTF‐CMV. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
- Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain.
- National Center of Microbiology, Instituto de Salud Carlos III, Majadahonda, Spain.
- Instituto de Agroquímica y Tecnología de Alimentos (IATA), Consejo Superior de Investigaciones Científicas (CSIC), Valencia, Spain.
- Department of Nephrology, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain.
ORCID-Profile: Mario Fernández-Ruiz, Marcos Nuévalos, Isabel Rodríguez-Goncer, Estéfani García-Ríos, Tamara Ruiz-Merlo, Natalia Redondo, Hernando Trujillo, Francisco López-Medrano, Rafael San Juan, Amado Andrés, Pilar Pérez-Romero, José María Aguado
Förderung
- Instituto de Salud Carlos III, co-funded by the European Union
- Generalitat Valenciana plan GenT
Zitieren
APA
Fernández-Ruiz, M., Nuévalos, M., Rodríguez-Goncer, I., García-Ríos, E., Ruiz-Merlo, T., Redondo, N., Trujillo, H., González, E., Polanco, N., Caso, J. M., Aparicio-Minguijón, E., López-Medrano, F., San Juan, R., Andrés, A., Pérez-Romero, P., & Aguado, J. M. (2026). Diagnostic Performance of Two Different Techniques to Quantify CMV‐Specific Cell‐Mediated Immunity in Intermediate‐Risk Seropositive Kidney Transplant Recipients. Transplant Infectious Disease, 28(1). https://doi.org/10.1111/tid.14437
Vancouver
Fernández-Ruiz M, Nuévalos M, Rodríguez-Goncer I, García-Ríos E, Ruiz-Merlo T, Redondo N, et al. Diagnostic Performance of Two Different Techniques to Quantify CMV‐Specific Cell‐Mediated Immunity in Intermediate‐Risk Seropositive Kidney Transplant Recipients. Transplant Infectious Disease. 2026;28(1). doi:10.1111/tid.14437
BibTeX
@article{FernndezRuiz2026,
author = {Fernández-Ruiz, Mario and Nuévalos, Marcos and Rodríguez-Goncer, Isabel and García-Ríos, Estéfani and Ruiz-Merlo, Tamara and Redondo, Natalia and Trujillo, Hernando and González, Esther and Polanco, Natalia and Caso, José María and Aparicio-Minguijón, Eduardo and López-Medrano, Francisco and San Juan, Rafael and Andrés, Amado and Pérez-Romero, Pilar and Aguado, José María},
title = {Diagnostic Performance of Two Different Techniques to Quantify CMV‐Specific Cell‐Mediated Immunity in Intermediate‐Risk Seropositive Kidney Transplant Recipients},
journal = {Transplant Infectious Disease},
year = {2026},
volume = {28},
number = {1},
doi = {10.1111/tid.14437}
}
EUVIMED